Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deanna Kamienski

Senior Deals Analyst, Biomedtracker

Deanna has been tracking deal-making activity in the biopharma and medtech industries since 2000. She is currently a Senior Deals Analyst for Biomedtracker and had previously contributed to the Strategic Transactions deals database. Deanna authors a Quarterly Statistics article and other monthly trend pieces for In Vivo. She holds a Bachelor of Science degree from the University of Vermont..

Latest From Deanna Kamienski

Deals In Depth: October 2022

Two $1bn+ alliances were penned in October. Financing reached $7.7bn in biopharma, $636m in device, and $140m in diagnostics.

Deals Financing

Dealmaking Quarterly Statistics, Q3 2022

During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.

Deals Companies

Financing Quarterly Statistics, Q3 2022

During Q3, biopharmas brought in an aggregate $18.1bn in financing and device company fundraising totaled $5.1bn; while in vitro diagnostic firms and research tools players raised $771m.

Deals Financing

Deals In Depth: September 2022

Just one $1bn+ alliance was penned in September compared to eight that were signed in August.

Deals Financing

Deals In Depth: August 2022

The height of the summer saw eight $1bn plus deals penned, including those by Pfizer and Roche.

Deals Financing

Deals In Depth: July 2022

Three $1B+ alliances were penned in July. Topping the list was a potential $2M deal between Skyhawk Therapeutics and Sanofi for the development of novel small molecules that modulate RNA splicing for challenging oncology and immunology targets. Skyhawk will grant Sanofi exclusive worldwide intellectual property rights to candidates discovered and developed under the collaboration. Skyhawk receives $54M up front and is also eligible to receive over $2B in potential milestone payments, as well as potential royalties on future sales. In the top July M&A by deal value, SD Biosensor and a consortium formed with private equity firm SJL Partners agreed to acquire US-based in vitro diagnostics company Meridian Bioscience in an all-cash transaction valued at approximately $1.53B. Founded in 1976, Meridian is a fully integrated life science company that manufactures, markets, and distributes a broad range of diagnostic test kits, purified reagents, and biopharmaceutical enabling technologies. The company has gained expertise through numerous acquisitions over the years including point-of-care testing firm Magellan Biosciences, GenePOC (develops POC molecular diagnostics for infectious diseases), and gastrointestinal diagnostics maker Exalenz Bioscience. Financing reached $3.97bn in biopharma, $851m in device, and $318m in diagnostics.

Deals Financing
See All
UsernamePublicRestriction

Register